Therapeutics News and Research

RSS

Shorter amyloid fibres more toxic than longer counterparts, says study

A major discovery is challenging accepted thinking about amyloids - the fibrous protein deposits associated with diseases such as Alzheimer's and Parkinson's - and may open up a potential new area for therapeutics.

4 Dec 2009

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptides.

4 Dec 2009

Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial

After two decades of scientifically and medically proven success in their field, Lightlake Therapeutics' experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatment for what the World Health Organisation has described as a global epidemic of unhealthy eating and obesity.

3 Dec 2009

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

iCo Therapeutics Inc. is pleased to announce that an overview of iCo-007, entitled "iCo-007 a VEGF "+" Agent for the Potential Treatment of Diabetic Macular Edema and Diabetic Retinopathy" will be presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics ("ISOPT"), a major international ocular conference.

3 Dec 2009

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate).

3 Dec 2009

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Allos Therapeutics, Inc. today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL). The registry, known as COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), is a global observational study that will enroll patients with newly-diagnosed PTCL and obtain data regarding longitudinal treatment patterns and outcomes.

3 Dec 2009

Psynova Neurotech, Roche collaborate in development of diagnostic immunoassays for schizophrenia treatment

Rules-Based Medicine, Inc. (RBM) today announced that Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of RBM, has executed an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia.

3 Dec 2009

Study: Stem cells from donor bone marrow may help repair heart damage

Adult stem cells may help repair heart tissue damaged by heart attack according to the findings of a new study to be published in the December 8 issue of the Journal of the American College of Cardiology. Results from the Phase I study show stem cells from donor bone marrow appear to help heart attack patients recover better by growing new blood vessels to bring more oxygen to the heart

3 Dec 2009

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated in pre-clinical animal models significant abilities to target and destroy CSCs.

3 Dec 2009

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

AclarusDx Alzheimer’s test now available as RUO product

ExonHit Therapeutics is pleased to announce that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and leading academic centers conducting clinical trials in Alzheimer’s disease.

3 Dec 2009

Adult stem cells may help repair heart tissue, reveals new study

2 Dec 2009

NHLBI awards stimulus funds for hemophilia drug research

PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million Challenge Grant award from the National Heart, Lung, and Blood Institute (NHLBI) as part of the National Institutes of Health (NIH).

2 Dec 2009

University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

Stemline Therapeutics, Inc., a private clinical stage biopharmaceutical company and leading developer of oncology compounds directed to cancer stem cells, today announced that The University of Texas M.D. Anderson Cancer Center (Houston, TX) and Stemline have entered into a research collaboration.

2 Dec 2009

Pycnogenol can improve microcirculation, retinal edema and visual acuity, reveals study

According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy.

2 Dec 2009

New study indicates pine bark may reduce progressing advanced stages of diabetic retinopathy

According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopathy, damage to the retina caused by leaky blood vessels, is a major cause of blindness in people with diabetes and is one of the most feared diabetic complications. In

2 Dec 2009

Future likely to witness improved therapies and novel drugs to treat lifestyle disorders

Increasing genomic knowledge will lead to the development of improved therapies to treat lifestyle disorders. In the near future, the European lifestyle disorders therapeutics market is set to witness enhanced therapies and novel drugs to treat such conditions and reduce the risk of co-morbidities.

2 Dec 2009

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

The Burrill Biotech Select Index managed to claw back almost half the value it lost in October. The Select's gain of 4.5 percent mirrored what was also an excellent month for the general markets with the Dow up 6.5 percent and the NASDAQ up 4.8 percent in value.

2 Dec 2009

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

Cambridge Research & Instrumentation, Inc. (CRi), a leader in biomedical imaging, today announced the results of a study demonstrating for the first time the capability to detect and automatically measure key activity indicators of cancer cell signal transduction pathways in intact tissue.

2 Dec 2009

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Cell Therapeutics, Inc. (CTI) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.

2 Dec 2009

Therapeutics News and Research

Shorter amyloid fibres more toxic than longer counterparts, says study

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Psynova Neurotech, Roche collaborate in development of diagnostic immunoassays for schizophrenia treatment

Study: Stem cells from donor bone marrow may help repair heart damage

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AclarusDx Alzheimer’s test now available as RUO product

Adult stem cells may help repair heart tissue, reveals new study

NHLBI awards stimulus funds for hemophilia drug research

University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

Pycnogenol can improve microcirculation, retinal edema and visual acuity, reveals study

New study indicates pine bark may reduce progressing advanced stages of diabetic retinopathy

Future likely to witness improved therapies and novel drugs to treat lifestyle disorders

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News